Bioelectronics Corp (OTCMKTS:BIEL) reported that its ActiPatch® product was featured in the Express Newspaper of the U.K. The paper is circulated to almost 400,000 customers, and therefore it will help increase the popularity of ActiPatch product.
The article highlights the results of recent Arthritis Research survey. It stated that there is severe impact of excessive drug use and pain among the 8.5 million people suffering from arthritis. The survey showed that 46% feel satisfied with the prevailing pain treatment they are getting from their healthcare professional or GP.
Almost 76% respondents stated that the pain stops them from living normal life. As many as 80% people said that their mobility is affected. Over 64% reported sleeping problems because of existing pain. The article highlights Bioelectronics ActiPatch’s mechanism of action and its efficacy in alleviating pain, which enhances quality life with less need of strong painkillers.
ActiPatch is clinically proven cure for osteoarthritis as established in an independently piloted double blind, randomized, placebo-controlled clinical study. The results were published in the journal Rheumatology. There was a statistically significant decline in pain and a noteworthy progress in the WOMAC² index. Additionally, subjects in the treatment group announced a statistically significant decline in NSAID against the placebo group.
Prior to this news, Bioelectronics reported that ActiPatch® was featured in the Daily Mail’s Sunday edition. The paper is circulated to over 1.5 million people. The article highlights the devices innovative technology and throws light on the firm’s new follow-up Observational trial.
The 6-month trial of 254 women and men with chronic pain indicate that it can be extremely effective and direct to improved quality life. Over 90% respondents reported continued relief. 61% people confirmed reduction in pain, and almost 90% reported improved sleep. The report has been accepted and was presented at the British Pain Society yearly scientific meeting.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Plans For Phase III Study of PLX-PAD
Pluristem Therapeutics Inc. (NASDAQ:PSTI) reported that it has obtained positive response from the U.S. FDA on the proposed Phase III study of its PLX-PAD cells in the cure of critical limb ischemia. This phase III study is planned to get a biologics license application.
Pluristem announced that the Phase 3 trial is a double blind, placebo controlled, randomized study in an estimated 250 subjects with CLI Rutherford Category 5, and are not suitable for revascularization. These subjects will be administered with 300 million cells, injected twice intramuscularly, with the second dose given after two months.
The first endpoint of the planned trial will be amputation free survival. Clinical sites will register subjects in the U.S. and Europe. Also, the study procedure has been given as a single pivotal study to European national competent authorities, after receiving scientific advice from the EMA. The approval is anticipated in the upcoming months.